Mpox Vaccine Hesitancy Among Brazilian Men Who Have Sex with Men: A National Cross-Sectional Study

• Published in: Vaccines (Basel) Vol. 12; no. 11; p. 1229
• Main Authors: Santos, Guilherme Reis de Santana, Ribeiro, Caíque Jordan Nunes, Santos Júnior, José Flávio Cerqueira dos, Almeida, Valdemar Silva, Nascimento, Rita de Cassia Dias, Barreto, Nilo Manoel Pereira Vieira, Sousa, Anderson Reis de, Bezerra-Santos, Márcio, Cepas, Lariane Angel, Fernandes, Ana Paula Morais, Mendes, Isabel Amélia Costa, Santos Júnior, Aires Garcia dos, Maronesi, Maria Luisa Pereira, Sousa, Álvaro Francisco Lopes de
• Format: Journal Article
• Language: English
• Published: 29.10.2024
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12111229

Background: Mpox is a viral zoonosis that has gained increased attention due to a global outbreak in 2022, significantly impacting men who have sex with men (MSM). Vaccination for this disease poses a public health challenge; because it carries a strong stigma, there may be greater hesitancy in vulnerable groups. Objectives: This study aimed to determine the prevalence and factors associated with Mpox vaccine hesitancy among Brazilian MSM. Methods: A cross-sectional study was conducted between September and December 2022 using an online survey targeted at MSM. Recruitment was carried out through social media and dating apps. The sample consisted of 1449 participants and the analysis involved bivariate logistic regression. Results: The prevalence of Mpox vaccine hesitancy was 7.57%. The significant factors associated with hesitancy were primarily related to sexual practices and attitudes towards Mpox exposure and diagnosis, such as not using “glory holes” (aOR: 19.82; 95% CI: 1.60–245.69), reluctance to undergo pre- and post-exposure testing for Mpox (aOR: 9.54; 95% CI: 5.52–16.48), and not knowing close contacts diagnosed with Mpox (aOR: 4.09; 95% CI: 1.72–9.73). Participants who would not take precautions after diagnosis (aOR: 3.00; 95% CI: 1.27–7.07) and those who would not disclose their serological status (aOR: 1.93; 95% CI: 1.13–3.30) also showed a higher likelihood of vaccine hesitancy. Conclusion: Public health strategies should address these factors to expand knowledge about vaccination barriers, plan educational campaigns with targeted messaging for the MSM population, and provide inclusive healthcare environments to increase vaccine acceptance and reduce Mpox transmission in vulnerable groups.